Former President, Chief Operating Officer and Director · Avalo Therapeutics, Inc. (AVTX)

Robert Moscato Jr.

A named executive officer of Avalo Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$270,685

Salary $70,685Stock awards $0

FY2017: $25,000

6th of 7 named executive officers at Avalo Therapeutics by FY2018 total.

7 named officers on file for Avalo Therapeutics, FY2018

Robert Moscato Jr.’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Avalo Therapeutics’s whole pay program stands against its peers

  • Avalo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 19, 2019 (DEF 14A).

Free

Get Robert Moscato Jr.’s full pay file as a PDF — free

More than this page: up to 10 years of Robert’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Robert Moscato Jr. compensation by year

Avalo Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Avalo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$25,000$70,685
Bonus$0$0
Stock awards$0$0
Option awards$0$0
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$200,000
Total$25,000$270,685

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed June 19, 2019, accession 0001628280-19-008116, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001628280-19-008116. Every figure is read from that document and cited to the page and table it appears in. Filed June 19, 2019.

$25K
$271K
FY17
FY18
SalaryAll other

Avalo Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Peter GreenleafFormer Chief Executive Officer$5,090,787
Mariam MorrisFormer Chief Financial Officer$687,468
Joseph MillerChief Financial Officer, Principal Executive Officer and Principal Financial Officer$672,985
James Harrell Jr.Executive Vice President, Marketing and External Communications$621,500
Pericles CaliasFormer Chief Scientific Officer$351,305
Robert Moscato Jr. · this pageFormer President, Chief Operating Officer and Director$270,685
Simon PedderFormer Executive Chairman of the Board$27,644

The full Avalo Therapeutics compensation record

free company brief

This page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robert Moscato Jr.'s compensation dossier · One-time report. No refunds.